Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2 (2013)

Peer-Reviewed Study · Barton DL, Liu H, Dakhil SR, Linquist B, Sloan JA, Nichols CR, McGinn TW, Stella PJ, Seeger GR, Sood A, Loprinzi CL · August 21, 2013

Barton DL et al., 2013-08-21: Phase III trial N07C2 of American ginseng 2000 mg/day versus placebo in 364 fatigued cancer survivors. The 4-week primary endpoint was not met (P = .07); the difference reached significance only at 8 weeks (P = .003).

A statistically significant difference was seen at 8 weeks with a change score of 20 (SD = 27) for the ginseng group and 10.3 (SD = 26.1) for the placebo group (P = .003).

Abstract, Results

Barton DL et al., 2013-08-21: Phase III trial N07C2 of American ginseng 2000 mg/day versus placebo in 364 fatigued cancer survivors. The 4-week primary endpoint was not met (P = .07); the difference reached significance only at 8 weeks (P = .003). Study type: randomized trial.